StemCell Therapy

Six of ten evaluable myelofibrosis patients who received GB2064 monotherapy for at least six months experienced a ? 1-grade reduction in collagen fibrosis of the bone marrow, validating LOXL2 as a clinical fibrosis target Six of ten evaluable myelofibrosis patients who received GB2064 monotherapy for at least six months experienced a ? 1-grade reduction in collagen fibrosis of the bone marrow, validating LOXL2 as a clinical fibrosis target

Read the rest here:
Topline Results from MYLOX-1 Trial Demonstrate Reduction in Fibrosis of the Bone Marrow in Patients with Myelofibrosis